Literature DB >> 3435125

Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models.

M N Dudley1, J Ericson, S H Zinner.   

Abstract

The effect of dose on the pharmacokinetics of ciprofloxacin in serum and urine following single intravenous doses of 100, 150, and 200 mg was studied in nine healthy volunteers. Mean peak levels in serum were 1.4, 2.0, and 3.2 mg/liter for the 100-, 150-, and 200-mg doses, respectively. The data on concentrations in serum were best described by a three-compartment pharmacokinetic model. The terminal half-life (from noncompartmental analysis) averaged between 4.2 and 4.6 h. Average urinary recovery ranged between 45.8 and 48.1%. The average renal clearance of ciprofloxacin was 2.9- to 3.4-fold greater than the measured creatinine clearance. Total serum and renal clearances decreased with increasing dose; however, this was not statistically significant (P greater than 0.05; repeated-measures analysis of variance). Ciprofloxacin was well tolerated by all subjects. In this dose range, ciprofloxacin pharmacokinetics are independent of dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435125      PMCID: PMC175039          DOI: 10.1128/AAC.31.11.1782

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.

Authors:  M A Gonzalez; A H Moranchel; S Duran; A Pichardo; J L Magana; B Painter; A Forrest; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

3.  Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.

Authors:  K Borner; G Höffken; H Lode; P Koeppe; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reinitz
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

4.  Dose ranging study and constant infusion evaluation of ciprofloxacin.

Authors:  G L Drusano; K I Plaisance; A Forrest; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

8.  Dose- and sex-independent disposition of ciprofloxacin.

Authors:  D Höffler; A Dalhoff; W Gau; D Beermann; A Michl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

10.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

View more
  8 in total

1.  Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

2.  Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition.

Authors:  R D Pryka; K A Rodvold; W Ting; S Levitsky; R W Frost; J T Lettieri
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 3.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 4.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.

Authors:  C R Marchbanks; J R McKiel; D H Gilbert; N J Robillard; B Painter; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 6.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

7.  Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.

Authors:  A C Panneton; M G Bergeron; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 8.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.